Helius Medical Creates Brain-Computer Interface Subsidiary

Neurotech firm Helius Medical Technologies Inc. has established a wholly-owned private subsidiary to develop non-implantable artificial intelligence (AI)-powered brain-computer interface (BCI) technology. The new entity is called Revelation Neuro Inc.

“We are thrilled to establish Revelation Neuro to pursue the development of a new gold standard of care for personalized neurorehabilitation using a non-implantable AI powered BCI combining our newly developed intellectual property (IP) with Helius’ existing IP. Our technology relies on its proven ability to modulate known target brain processes and trigger therapeutic responses by using translingual stimulation without risky implantation. We believe Revelation Neuro’s BCI technology will be a unique and less invasive therapeutic option,” Helius Medical President/CEO Dane Andreeff said.

Revelation Neuro is a private subsidiary fully owned by Helius Medical Technologies. Helius intends to assign its newly developed IP and to license its existing IP to Revelation Neuro. Leveraging more than $70 million invested to date in developing a novel and proprietary neuromodulation mechanism of action and data gathering will allow expedited development of Revelation Neuro’s AI powered BCI. Helius does not intend to invest significant additional capital in the wholly owned subsidiary but instead expects it to be financed through third-party outside sources.

“Revelation Neuro is focused on maximizing the positive effect of neuromodulation by applying AI to optimize individual response to translingual stimulation,” Andreeff continued. “Helius’ dataset, comprised of more than five years of movement dysfunction clinical evidence from over 400 subjects, will serve as the initial foundation for AI algorithm development to which new patient data will then be added to optimize the algorithm and enable a precise and personalized approach to motor function rehabilitation. Revolutionary BCI-enabled improvement in functional rehabilitation is the initial focus of Revelation Neuro’s efforts, with the potential in the future to address neurological conditions including cognitive deficit, mood and behavior disorders.”

Helius Medical Technologies is a neurotech company focused on neurologic deficits using an orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people with neurologic diseases. The company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS).